Men and women aged 18 to 75 with a clinical diagnosis of chronic atopic dermatitis (eczema) for at least two years, may qualify to participate in this study. Individuals must have moderate to severe disease, involving 10% or more of their body. To be eligible, participants must also have a recent history (within 12 months) of inadequate response to treatment with topical medications, or for whom topical treatments are otherwise medically inadvisable.
Participants will receive investigational medication via injection (either active study drug or placebo). Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last up to 68 weeks and involve about 30 visits to the study centre.
Email Tina Craig, Clinical Research Coordinator at DermEffects to register.